Trial reportAesthetic plastic surgery2026
A Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.
Trial report in Aesthetic plastic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe efficacy of non-invasive ultrasound skin tightening (e.g., Sofwave) relies on fibroblast mechanotransduction, a process impaired in obesity. The widespread use of GLP-1 receptor agonists (GLP-1RAs) like semaglutide for weight loss introduces a dynamic metabolic variable that may further alter dermal tissue state. The optimal timing between these interventions is unknown and difficult to study clinically.
methodsWe conducted a first fully computational, mechanistically constrained virtual randomized trial. A cohort of 20,000 digital twins (BMI >30 kg/m
resultsFibroblast response to identical mechanical stress was gated by insulin resistance (IR). Higher IR raised the activation threshold from 36.8 to 47.9 kPa and reduced max cycling probability from 0.34 to 0.21. Semaglutide timing created a non-monotonic effect: 3-month pre-treatment yielded the greatest net benefit (+0.092 cycling AUC, +41% collagen density). This benefit resulted from balancing direct fibroblast priming (+0.118 AUC) against indirect adipose support loss (-0.026 AUC). Prolonged (6-month) pre-treatment was detrimental in high-IR phenotypes (90th percentile ΔAUC: -0.006). The 3-month pre-treatment arm also produced a more isotropic ECM (anisotropy index: 0.26 vs. 0.41 in control).
conclusionSofwave's remodelling efficacy is determined by tissue mechanosensitivity, which is dynamically and non-uniformly modulated by GLP-1RA therapy. These simulations identify a potential therapeutic window, suggesting that initiating mechanical stimulation during early metabolic improvement but before significant adipose support loss may optimize dermal outcomes in obese patients. These computational findings are hypothesis-generating and require experimental validation through ex vivo and clinical studies before clinical translation. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
42310090What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.